1
|
Calumenin knockdown, by intronic artificial microRNA, to improve expression efficiency of the recombinant human coagulation factor IX. Biotechnol Lett 2022; 44:713-728. [PMID: 35412165 DOI: 10.1007/s10529-022-03249-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 03/25/2022] [Indexed: 11/02/2022]
Abstract
OBJECTIVES To improve the expression efficiency of recombinant hFIX, by enhancing its γ-carboxylation, which is inhibited by Calumenin (CALU), we used intronic artificial microRNAs (amiRNAs) for the CALU downregulation. METHODS Two human CALU (hCALU)-specific amiRNAs were designed, validated and inserted within a truncated form of the hFIX intron 1, in either 3'- or 5'-untranslated regions of the hFIX cDNA, in an expression vector. After transfections of a human cell line with the recombinant constructs, processing of the miRNAs confirmed by RT-PCR, using stem-loop primers. The hFIX and hCALU expression assessments were done based on RT-PCR results. The Gamma(γ)-carboxylation of the expressed hFIX was examined by a barium citrate precipitation method, followed by Enzyme-Linked Immunosorbent Assay. RESULTS Efficient CALU down regulations, with more than 30-fold decrease, occurred in the cells carrying either of the two examined the 3'-located amiRNAs. The CALU downregulation in the same cells doubled the FIX γ-carboxylation, although the transcription of the FIX decreased significantly. On the other hand, while the expression of the amiRNAs from the 5'-located intron had no decreasing effect on the expression level of CALU, the level of hFIX transcription in these cells increased almost twofold compared to the construct without amiRNA. CONCLUSION The CALU downregulation, consistent with efficient hFIX γ-carboxylation, occurred in the cells carrying either of the two amiRNAs containing constructs, although it was affected by the locations of the amiRNA carrying introns, suggesting a possible need to optimize the conditions for the amiRNAs expression.
Collapse
|
2
|
Forier C, Boschetti E, Ouhammouch M, Cibiel A, Ducongé F, Nogré M, Tellier M, Bataille D, Bihoreau N, Santambien P, Chtourou S, Perret G. DNA aptamer affinity ligands for highly selective purification of human plasma-related proteins from multiple sources. J Chromatogr A 2017; 1489:39-50. [PMID: 28179082 DOI: 10.1016/j.chroma.2017.01.031] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Revised: 01/04/2017] [Accepted: 01/06/2017] [Indexed: 01/18/2023]
Abstract
Nucleic acid aptamers are promising ligands for analytical and preparative-scale affinity chromatography applications. However, a full industrial exploitation requires that aptamer-grafted chromatography media provide a number of high technical standards that remained largely untested. Ideally, they should exhibit relatively high binding capacity associated to a very high degree of specificity. In addition, they must be highly resistant to harsh cleaning/sanitization conditions, as well as to prolonged and repeated exposure to biological environment. Here, we present practical examples of aptamer affinity chromatography for the purification of three human therapeutic proteins from various sources: Factor VII, Factor H and Factor IX. In a single chromatographic step, three DNA aptamer ligands enabled the efficient purification of their target protein, with an unprecedented degree of selectivity (from 0.5% to 98% of purity in one step). Furthermore, these aptamers demonstrated a high stability under harsh sanitization conditions (100h soaking in 1M NaOH). These results pave the way toward a wider adoption of aptamer-based affinity ligands in the industrial-scale purification of not only plasma-derived proteins but also of any other protein in general.
Collapse
Affiliation(s)
| | | | | | | | - Frédéric Ducongé
- CEA, I2BM, MIRCen, UMR 9199, Université Paris Saclay, Fontenay aux Roses, France
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Yen CH, Yang TS, Lin YS, Lee MH, Yu KC, Huang CL, Hsieh HH, Tu CF. A galactopoiesis accordant yield of functional recombinant human factor IX from homozygous transgenic pigs requires a large amount of vitamin K supplementation. Transgenic Res 2016; 25:545-51. [PMID: 27160182 DOI: 10.1007/s11248-016-9948-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Accepted: 03/04/2016] [Indexed: 11/26/2022]
Abstract
Transgenic pigs failed to accord milk yield curve to lactate rhFIX-a vitamin K (VK) dependent protein even fed with VK enriched to 8 times higher than nutritional requirement. A further higher VK supplementation may be required. Homozygous transgenic sows (n = 4, 200 kg) at their 3rd nursing were divided into control and treatment groups and respectively received VK enriched and further menadione (soluble VK) supplemented diet (220 mg/kg VK enriched diet) for 33 days. At next lactation, control sows than received treatment and previous treated were fed on control diet. Results revealed that menadione treatment increased milk bioactivity of rhFIX from the 7th day of 73 to the 21st day of 153 IU/mL; it gradually decreased to 96 IU/mL on 35th day of lactation. Under control feeding, bioactivity remained relatively unchanged. However, milk rhFIX concentration and ratio of activated rhFIX responded little to the treatment. The menadione-induced bioactivity curve agrees with the known lactation pattern of sow means rhFIX secretion is still galactopoietic but requires high VK intake to show. The ineffectual VK spend on lactational carboxylation might be common in other mammary VK dependent expression system but can be effectively overcome by a high supplementation of menadione with a 5-folds improvement in quality.
Collapse
Affiliation(s)
- Chon-Ho Yen
- Division of Animal Technology, Animal Technology Laboratories, Agriculture Technology Research Institute, No.1, Ln. 51, Dahu Rd., Xiangshan Dist., Hsinchu, 30093, Taiwan, ROC
| | - Tien-Shuh Yang
- Department of Biotechnology and Animal Science, National Ilan University, 1, Set. 1, Shen-Lung Rd, Ilan, 26041, Taiwan, ROC
| | - Yin-Shen Lin
- Division of Animal Technology, Animal Technology Laboratories, Agriculture Technology Research Institute, No.1, Ln. 51, Dahu Rd., Xiangshan Dist., Hsinchu, 30093, Taiwan, ROC
| | - Meng-Hwan Lee
- Division of Animal Technology, Animal Technology Laboratories, Agriculture Technology Research Institute, No.1, Ln. 51, Dahu Rd., Xiangshan Dist., Hsinchu, 30093, Taiwan, ROC
| | - Kuo-Cheng Yu
- Division of Animal Technology, Animal Technology Laboratories, Agriculture Technology Research Institute, No.1, Ln. 51, Dahu Rd., Xiangshan Dist., Hsinchu, 30093, Taiwan, ROC
| | - Chung-Lin Huang
- Division of Animal Technology, Animal Technology Laboratories, Agriculture Technology Research Institute, No.1, Ln. 51, Dahu Rd., Xiangshan Dist., Hsinchu, 30093, Taiwan, ROC
| | - How-Hong Hsieh
- Department of Animal Science, National Pingtung University of Science and Technology, No. 1, Sheufu Road, Neipu, Pingtung, 912, Taiwan, ROC
| | - Ching-Fu Tu
- Division of Animal Technology, Animal Technology Laboratories, Agriculture Technology Research Institute, No.1, Ln. 51, Dahu Rd., Xiangshan Dist., Hsinchu, 30093, Taiwan, ROC.
| |
Collapse
|
4
|
Zhao J, Xu W, Ross JW, Walters EM, Butler SP, Whyte JJ, Kelso L, Fatemi M, Vanderslice NC, Giroux K, Spate LD, Samuel MS, Murphy CN, Wells KD, Masiello NC, Prather RS, Velander WH. Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk. Sci Rep 2015; 5:14176. [PMID: 26387706 PMCID: PMC4585688 DOI: 10.1038/srep14176] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Accepted: 07/22/2015] [Indexed: 11/20/2022] Open
Abstract
Both the low animal cell density of bioreactors and their ability to post-translationally process recombinant factor IX (rFIX) limit hemophilia B therapy to <20% of the world’s population. We used transgenic pigs to make rFIX in milk at about 3,000-fold higher output than provided by industrial bioreactors. However, this resulted in incomplete γ-carboxylation and propeptide cleavage where both processes are transmembrane mediated. We then bioengineered the co-expression of truncated, soluble human furin (rFurin) with pro-rFIX at a favorable enzyme to substrate ratio. This resulted in the complete conversion of pro-rFIX to rFIX while yielding a normal lactation. Importantly, these high levels of propeptide processing by soluble rFurin did not preempt γ-carboxylation in the ER and therefore was compartmentalized to the Trans-Golgi Network (TGN) and also to milk. The Golgi specific engineering demonstrated here segues the ER targeted enhancement of γ-carboxylation needed to biomanufacture coagulation proteins like rFIX using transgenic livestock.
Collapse
Affiliation(s)
- Jianguo Zhao
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA.,State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China, 100101
| | - Weijie Xu
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, 207 Othmer Hall, University of Nebraska, Lincoln 68588, USA
| | - Jason W Ross
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA.,Department of Animal Science, Iowa State University, Ames, IA 50011, USA
| | - Eric M Walters
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | | | - Jeff J Whyte
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | - Lindsey Kelso
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | - Mostafa Fatemi
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, 207 Othmer Hall, University of Nebraska, Lincoln 68588, USA
| | - Nicholas C Vanderslice
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, 207 Othmer Hall, University of Nebraska, Lincoln 68588, USA
| | - Keith Giroux
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | - Lee D Spate
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | - Melissa S Samuel
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | - Cliff N Murphy
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | - Kevin D Wells
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | | | - Randall S Prather
- National Swine Resource and Research Center &Division of Animal Science, University of Missouri, Columbia, MO 65211, USA
| | - William H Velander
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, 207 Othmer Hall, University of Nebraska, Lincoln 68588, USA
| |
Collapse
|
5
|
Vanderslice NC, Messer AS, Vadivel K, Bajaj SP, Phillips M, Fatemi M, Xu W, Velander WH. Quantifying vitamin K-dependent holoprotein compaction caused by differential γ-carboxylation using high-pressure size exclusion chromatography. Anal Biochem 2015; 479:6-14. [PMID: 25804408 PMCID: PMC4428943 DOI: 10.1016/j.ab.2015.03.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 03/09/2015] [Accepted: 03/15/2015] [Indexed: 11/19/2022]
Abstract
This study uses high-pressure size exclusion chromatography (HPSEC) to quantify divalent metal ion (X(2+))-induced compaction found in vitamin K-dependent (VKD) proteins. Multiple X(2+) binding sites formed by the presence of up to 12 γ-carboxyglutamic acid (Gla) residues are present in plasma-derived FIX (pd-FIX) and recombinant FIX (r-FIX). Analytical ultracentrifugation (AUC) was used to calibrate the Stokes radius (R) measured by HPSEC. A compaction of pd-FIX caused by the filling of Ca(2+) and Mg(2+) binding sites resulted in a 5 to 6% decrease in radius of hydration as observed by HPSEC. The filling of Ca(2+) sites resulted in greater compaction than for Mg(2+) alone where this effect was additive or greater when both ions were present at physiological levels. Less X(2+)-induced compaction was observed in r-FIX with lower Gla content populations, which enabled the separation of biologically active r-FIX species from inactive ones by HPSEC. HPSEC was sensitive to R changes of approximately 0.01nm that enabled the detection of FIX compaction that was likely cooperative in nature between lower avidity X(2+) sites of the Gla domain and higher avidity X(2+) sites of the epidermal growth factor 1 (EGF1)-like domain.
Collapse
Affiliation(s)
- Nicholas C Vanderslice
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
| | - Amanda S Messer
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA; Protein Science Laboratory, UCLA/Orthopaedic Hospital, Department of Orthopaedic Surgery and Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Kanagasabai Vadivel
- Protein Science Laboratory, UCLA/Orthopaedic Hospital, Department of Orthopaedic Surgery and Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - S Paul Bajaj
- Protein Science Laboratory, UCLA/Orthopaedic Hospital, Department of Orthopaedic Surgery and Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Martin Phillips
- UCLA-DOE Biochemistry Instrumentation Facility, Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Mostafa Fatemi
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
| | - Weijie Xu
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
| | - William H Velander
- Protein Purification and Characterization Laboratories, Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
| |
Collapse
|
6
|
|
7
|
Recombinant human factor IX produced from transgenic porcine milk. BIOMED RESEARCH INTERNATIONAL 2014; 2014:315375. [PMID: 24955355 PMCID: PMC4052152 DOI: 10.1155/2014/315375] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Revised: 04/15/2014] [Accepted: 04/21/2014] [Indexed: 02/06/2023]
Abstract
Production of biopharmaceuticals from transgenic animal milk is a cost-effective method for highly complex proteins that cannot be efficiently produced using conventional systems such as microorganisms or animal cells. Yields of recombinant human factor IX (rhFIX) produced from transgenic porcine milk under the control of the bovine α-lactalbumin promoter reached 0.25 mg/mL. The rhFIX protein was purified from transgenic porcine milk using a three-column purification scheme after a precipitation step to remove casein. The purified protein had high specific activity and a low ratio of the active form (FIXa). The purified rhFIX had 11.9 γ-carboxyglutamic acid (Gla) residues/mol protein, which approached full occupancy of the 12 potential sites in the Gla domain. The rhFIX was shown to have a higher isoelectric point and lower sialic acid content than plasma-derived FIX (pdFIX). The rhFIX had the same N-glycosylation sites and phosphorylation sites as pdFIX, but had a higher specific activity. These results suggest that rhFIX produced from porcine milk is physiologically active and they support the use of transgenic animals as bioreactors for industrial scale production in milk.
Collapse
|
8
|
Wendeler M, Pabst TM, Wang J, Strouse RJ, Wang X, Hunter AK. Process-scale purification and analytical characterization of highly gamma-carboxylated recombinant human prothrombin. J Chromatogr A 2014; 1325:171-8. [PMID: 24369997 DOI: 10.1016/j.chroma.2013.12.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2013] [Revised: 11/01/2013] [Accepted: 12/06/2013] [Indexed: 11/15/2022]
Abstract
Prothrombin (coagulation Factor II) is a complex multidomain glycoprotein that plays a central role in blood coagulation. It is the zymogen precursor to the protease thrombin that catalyzes the formation of the fibrin clot and regulates a multitude of other cellular responses related to coagulation and hemostasis. For the biological activity of prothrombin, the vitamin K dependent posttranslational modification of glutamic acid residues to gamma-carboxylglutamic acid is of crucial importance. Prothrombin can be recombinantly expressed using mammalian cell culture. However, the product is a heterogeneous mixture of variants with different degrees of carboxylation, requiring separation of closely related charge isoforms. A second challenge for purification is the need to remove traces of the product-related impurity thrombin, a protease, to extremely low levels. In this work, we describe a purification strategy that provides solutions to both challenges and results in an efficient and robust process for active recombinant prothrombin. We also describe the analytical characterization of recombinant prothrombin by HPLC, LC-MS/MS, and complementary biochemical assays.
Collapse
Affiliation(s)
- Michaela Wendeler
- MedImmune LLC, Department of Purification Process Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA
| | - Timothy M Pabst
- MedImmune LLC, Department of Purification Process Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA
| | - Jihong Wang
- MedImmune LLC, Department of Analytical Biotechnology, One MedImmune Way, Gaithersburg, MD 20878, USA
| | - Robert J Strouse
- MedImmune LLC, Department of Analytical Biotechnology, One MedImmune Way, Gaithersburg, MD 20878, USA
| | - Xiangyang Wang
- MedImmune LLC, Department of Purification Process Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA
| | - Alan K Hunter
- MedImmune LLC, Department of Purification Process Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA.
| |
Collapse
|
9
|
Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87 Suppl 1:S33-9. [PMID: 22389200 DOI: 10.1002/ajh.23146] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2012] [Accepted: 01/30/2012] [Indexed: 02/03/2023]
Abstract
Recombinant DNA technology and protein engineering are creating hope that we can address ongoing challenges in hemophilia care such as reducing the costs of therapy, increasing the availability to the developing world, and improving the functional properties of these proteins. Technological advances to improve the half-life of recombinant clotting factors have brought long-acting clotting factors for hemophilia replacement therapy closer to reality. Preclinical and clinical trial results are reviewed as well as the potential benefits and risks of these novel therapies.
Collapse
Affiliation(s)
- Steven W Pipe
- Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
| |
Collapse
|
10
|
Sun YL, Chang YS, Lin YS, Yen CH. Pilot production of recombinant human clotting factor IX from transgenic sow milk. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 898:78-89. [PMID: 22578515 DOI: 10.1016/j.jchromb.2012.04.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2012] [Revised: 03/28/2012] [Accepted: 04/17/2012] [Indexed: 11/27/2022]
Abstract
Valuable pharmaceutical proteins produced from the mammary glands of transgenic livestock have potential use in the biomedical industry. In this study, recombinant human clotting factor IX (rhFIX) produced from transgenic sow milk for preclinical animal studies have been established. The transgenic sow milk was skimmed and treated with sodium phosphate buffer to remove abundant casein protein. Then, the γ-carboxylated rhFIX fraction was segregated through the Q Sepharose chromatography from uncarboxylated one. For safety issue, the process included virus inactivation by solvent/detergent (S/D) treatment. Subsequently, the S/D treated sample was loaded into the Heparin Sepharose column to recover the rhFIX fraction, which was then reapplied to the Heparin Sepharose column to enhance rhFIX purity and lower the ratio of activated form rhFIX (rhFIXa) easily. This was possible due to the higher affinity of the Heparin affinity sorbent for rhFIXa than for the rhFIX zymogen. Furthermore, an IgA removal column was used to eliminate porcine IgA in purified rhFIX. Finally, nanofiltration was performed for viral clearance. Consequently, a high-quality rhFIX product was produced (approximately 700 mg per batch). Other values for final rhFIX preparation were as follows: purity, >99%; average specific activity, 415.6±57.7 IU/mL and total milk impurity, <0.5 ng/mg. This is the first report that described the whole process and stable production of bioactive rhFIX from transgenic sow milk. The overall manufacturing process presented here has the potential for industrial production of rhFIX for treatment of hemophilia B patients.
Collapse
Affiliation(s)
- Yu-ling Sun
- Division of Biotechnology, Animal Technology Institute Taiwan, P.O. Box 23, Chunan 350, Miaoli, Taiwan, ROC
| | | | | | | |
Collapse
|
11
|
Vatandoost J, Zomorodipour A, Sadeghizadeh M, Aliyari R, Bos MHA, Ataei F. Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ-carboxylation of a human vitamin K-dependent protein by the insect enzyme. Biotechnol Prog 2011; 28:45-51. [PMID: 22012919 DOI: 10.1002/btpr.723] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2011] [Revised: 08/03/2011] [Indexed: 01/12/2023]
Abstract
The Drosophila γ-glutamyl carboxylase (dγC) has substrate recognition properties similar to that of the vertebrate γ-carboxylase (γC), and its carboxylated product yield, in vitro, was shown to be more than that obtained with the human enzyme. However, whether the Drosophila enzyme is able to γ-carboxylate the human vitamin K-dependent (VKD) proteins, such as the human coagulation factor IX (hFIX), as synthesized in cultured Drosophila cells was not known. To examine this possibility, the Drosophila Schnider (S2) cell line was transfected with a metallothionein promoter-regulated hFIX-expressing plasmid. After induction with copper ion, expression efficiency of the active hFIX was analyzed by performing enzyme-linked immunosorbent assey (ELISA) and coagulation test on the culture supernatant of the transfected S2 cells during 72 h of postinduction. In comparison with Chinese hamster ovary cell line, S2 cells showed higher (≈ 12-fold) expression level of the hFIX. The γ-carboxylation of the Drosophila-derived hFIX was confirmed by evaluation of the expressed protein, after being precipitated with barium citrate. The biological activity of the S2 cell-derived hFIX indicated the capability of S2 cells to fulfill the required γ-carboxylation of the expressed hFIX. Coexpression of the human γ-glutamyl carboxylases (hγC) was also shown to improve both expression and γ-carboxylation of the hFIX. This is the first in vivo data to describe the ability of the dγC to recognize the human-based propeptide as substrate, which is an essential step for production of biologically active γ-carboxylated VKD proteins.
Collapse
Affiliation(s)
- Jafar Vatandoost
- Department of Genetics, Tarbiat Modares University, Tehran, Iran
| | | | | | | | | | | |
Collapse
|
12
|
Whyte JJ, Prather RS. Genetic modifications of pigs for medicine and agriculture. Mol Reprod Dev 2011; 78:879-91. [PMID: 21671302 PMCID: PMC3522184 DOI: 10.1002/mrd.21333] [Citation(s) in RCA: 142] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2011] [Accepted: 05/09/2011] [Indexed: 12/18/2022]
Abstract
Genetically modified swine hold great promise in the fields of agriculture and medicine. Currently, these swine are being used to optimize production of quality meat, to improve our understanding of the biology of disease resistance, and to reduced waste. In the field of biomedicine, swine are anatomically and physiologically analogous to humans. Alterations of key swine genes in disease pathways provide model animals to improve our understanding of the causes and potential treatments of many human genetic disorders. The completed sequencing of the swine genome will significantly enhance the specificity of genetic modifications, and allow for more accurate representations of human disease based on syntenic genes between the two species. Improvements in both methods of gene alteration and efficiency of model animal production are key to enabling routine use of these swine models in medicine and agriculture.
Collapse
Affiliation(s)
- Jeffrey J. Whyte
- National Swine Resource and Research Center, University of Missouri, Columbia, MO, U.S.A
- Department of Biomedical Sciences, University of Missouri, Columbia, MO, U.S.A
- Division of Animal Science, University of Missouri, Columbia, MO, U.S.A
| | - Randall S. Prather
- National Swine Resource and Research Center, University of Missouri, Columbia, MO, U.S.A
- Division of Animal Science, University of Missouri, Columbia, MO, U.S.A
| |
Collapse
|
13
|
Gil GC, Iliff B, Cerny R, Velander WH, Van Cott KE. High throughput quantification of N-glycans using one-pot sialic acid modification and matrix assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem 2010; 82:6613-20. [PMID: 20586471 DOI: 10.1021/ac1011377] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Appropriate glycosylation of recombinant therapeutic glycoproteins has been emphasized in biopharmaceutical industries because the carbohydrate component can affect safety, efficacy, and consistency of the glycoproteins. Reliable quantification methods are essential to ensure consistency of their products with respect to glycosylation, particularly sialylation. Mass spectrometry (MS) has become a popular tool to analyze glycan profiles and structures, showing high resolution and sensitivity with structure identification ability. However, quantification of sialylated glycans using MS is not as reliable because of the different ionization efficiency between neutral and acidic glycans. We report here that amidation in mild acidic conditions can be used to neutralize acidic N-glycans still attached to the protein. The resulting amidated N-glycans can then be released from the protein using PNGase F, and labeled with permanent charges on the reducing end to avoid any modification and the formation of metal adducts during MS analysis. The N-glycan modification, digestion, and desalting steps were performed using a single-pot method that can be done in microcentrifuge tubes or 96-well microfilter plates, enabling high throughput glycan analysis. Using this method we were able to perform quantitative MALDI-TOF MS of a recombinant human glycoprotein to determine changes in fucosylation and changes in sialylation that were in very good agreement with a normal phase HPLC oligosaccharide mapping method.
Collapse
Affiliation(s)
- Geun-Cheol Gil
- Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, USA
| | | | | | | | | |
Collapse
|
14
|
He Z, Zhao Y, Mei G, Li N, Chen Y. Could protein tertiary structure influence mammary transgene expression more than tissue specific codon usage? Transgenic Res 2010; 19:519-33. [PMID: 20563642 PMCID: PMC2902731 DOI: 10.1007/s11248-010-9411-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2009] [Accepted: 05/19/2010] [Indexed: 12/03/2022]
Abstract
Animal mammary glands have been successfully employed to produce therapeutic recombinant human proteins. However, considerable variation in animal mammary transgene expression efficiency has been reported. We now consider whether aspects of codon usage and/or protein tertiary structure underlie this variation in mammary transgene expression.
Collapse
Affiliation(s)
- Zuyong He
- State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, 510006, Guangzhou, People's Republic of China
| | | | | | | | | |
Collapse
|
15
|
Gil GC, Velander WH, Van Cott KE. Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk. Glycobiology 2008; 18:526-39. [PMID: 18456721 DOI: 10.1093/glycob/cwn035] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Glycosylation of recombinant proteins is of particular importance because it can play significant roles in the clinical properties of the glycoprotein. In this work, the N-glycan structures of recombinant human Factor IX (tg-FIX) produced in the transgenic pig mammary gland were determined. The majority of the N-glycans of transgenic pig-derived Factor IX (tg-FIX) are complex, bi-antennary with one or two terminal N-acetylneuraminic acid (Neu5Ac) moieties. We also found that the N-glycan structures of tg-FIX produced in the porcine mammary epithelial cells differed with respect to N-glycans from glycoproteins produced in other porcine tissues. tg-FIX contains no detectable Neu5Gc, the sialic acid commonly found in porcine glycoproteins produced in other tissues. Additionally, we were unable to detect glycans in tg-FIX that have a terminal Galalpha(1,3)Gal disaccharide sequence, which is strongly antigenic in humans. The N-glycan structures of tg-FIX are also compared to the published N-glycan structures of recombinant human glycoproteins produced in other transgenic animal species. While tg-FIX contains only complex structures, antithrombin III (goat), C1 inhibitor (rabbit), and lactoferrin (cow) have both high mannose and complex structures. Collectively, these data represent a beginning point for the future investigation of species-specific and tissue/cell-specific differences in N-glycan structures among animals used for transgenic animal bioreactors.
Collapse
Affiliation(s)
- Geun-Cheol Gil
- Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
| | | | | |
Collapse
|
16
|
Prather RS. Nuclear remodeling and nuclear reprogramming for making transgenic pigs by nuclear transfer. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2007; 591:1-13. [PMID: 17176551 DOI: 10.1007/978-0-387-37754-4_1] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
A better understanding of the cellular and molecular events that occur when a nucleus is transferred to the cytoplasm of an oocyte will permit the development of improved procedures for performing nuclear transfer and cloning. In some cases it appears that the gene(s) are reprogrammed, while in other cases there appears to be little effect on gene expression. Not only does the pattern of gene expression need to be reprogrammed, but other structures within the nucleus also need to be remodeled. While nuclear transfer works and transgenic and knockout animals can be created, it still is an inefficient process. However, even with the current low efficiencies this technique has proved very valuable for the production of animals that might be useful for tissue or organ transplantation to humans.
Collapse
Affiliation(s)
- Randall S Prather
- Division of Animal Science, Food for the 21st Century, College of Food, Agriculture & Natural Resources, University of Missouri-Columbia, 920 East Campus Drive, E125 ASRC, Columbia, Missouri 65211-5300, USA.
| |
Collapse
|
17
|
Mullen SF, Rosenbaum M, Critser JK. The effect of osmotic stress on the cell volume, metaphase II spindle and developmental potential of in vitro matured porcine oocytes. Cryobiology 2007; 54:281-9. [PMID: 17485076 PMCID: PMC1989776 DOI: 10.1016/j.cryobiol.2007.03.005] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2007] [Revised: 03/28/2007] [Accepted: 03/29/2007] [Indexed: 11/22/2022]
Abstract
Porcine animal models are used to advance our understanding of human physiology. Current research is also directed at methods to produce transgenic pigs. Cryobanking gametes and embryos can facilitate the preservation of valuable genotypes, yet cryopreserving oocytes from pigs has proven very challenging. The current study was designed to understand the effects of anisotonic solutions on in vitro matured porcine oocytes as a first step toward designing improved cryopreservation procedures. We hypothesized that the proportion of oocytes demonstrating a normal spindle apparatus and in vitro developmental potential would be proportional to the solution osmolality. Oocytes were incubated for 10 min at 38 degrees C in various hypo- or hypertonic solutions, and an isotonic control solution and then assessed for these two parameters. Our results support the hypothesis, with an increasing proportion of spindles showing a disrupted structure as the levels of anisotonic exposure diverge from isotonic. Only about half of the oocytes maintained developmental potential after exposure to anisotonic solutions compared to untreated controls. Oocyte volume displayed a linear response to anisotonic solutions as expected, with an estimated relative osmotically inactive cell volume of 0.178. The results from this study provide initial biophysical data to characterize porcine oocytes. The results from future experiments designed to determine the membrane permeability to various cryoprotectants will allow predictive modeling of optimal cryopreservation parameters and provide a basis for designing improved cryopreservation procedures.
Collapse
Affiliation(s)
- S F Mullen
- The Comparative Medicine Center and Department of Veterinary Pathobiology, The University of Missouri at Columbia, Columbia, MO 65211, USA
| | | | | |
Collapse
|
18
|
|
19
|
Fee CJ, Chand A. Design Considerations for the Batch Capture of Proteins from Raw Whole Milk by Ion Exchange Chromatography. Chem Eng Technol 2005. [DOI: 10.1002/ceat.200500124] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
20
|
Kim MO, Kim SH, Lee SR, Kim KS, Min KS, Lee HT, Kim SJ, Ryoo ZY. Transgene expression of biological active recombinant human granulocyte-colony stimulating factor (hG-CSF) into mouse urine. Life Sci 2005; 78:1003-9. [PMID: 16168442 DOI: 10.1016/j.lfs.2005.06.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2004] [Accepted: 06/08/2005] [Indexed: 10/25/2022]
Abstract
We have generated transgenic mice that expressed human granulocyte-colony stimulating factor (hG-CSF) in their urine. In particular, the expression plasmid DNA containing mouse uroplakin II promoter was used to direct the uroepithelium-specific transcription of the transgene. In this study, the hG-CSF transcript was detected only in bladder, as was determined by RT-PCR analysis. Furthermore, hG-CSF protein was detected in the suprabasal layer of the uroepithelium and ureter, as was demonstrated by immunohistochemistry. The hG-CSF was secreted into urine at a high level (approx. 500 pg/ml), and it was able to enhance the proliferation of DMSO treated HL-60 cells, suggesting that the transgenic urine-derived hG-CSF was bioactive. However, the recombinant hG-CSF was leaked to peripheral circulation system. To examine the relationship between hG-CSF in the blood stream and the proliferation of hematopoietic cells, we tested the transgenic mouse blood with hematocrit analysis. An increase of the total number of neutrophils in the transgenic mice peripheral blood was not observed; therefore, the leakage of human G-CSF can probably be expected to do no harm to the transgenic mouse. Our results demonstrate that bladder can be safely used as a bioreactor to produce biologically important substances such as recombinant G-CSF.
Collapse
Affiliation(s)
- Myoung Ok Kim
- School of Lifesciences and Biotechnology, College of Natural Sciences, Kyungpook National University, Daegu, 702-701, Korea
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
The past 10 years of clinical experience have demonstrated the safety and efficacy of recombinant clotting factors. With the adoption of prophylactic strategies, there has been considerable progress in avoiding the complications of hemophilia. Now, insights from our understanding of clotting factor structure and function, mechanisms of hemophilia and inhibitors, gene therapy advances and a worldwide demand for clotting factor concentrates leave us on the brink of embracing targeted bioengineering strategies to further improve hemophilia therapeutics. The ability to bioengineer recombinant clotting factors with improved function holds promise to overcome some of the limitations in current treatment, the high costs of therapy and increase availability to a broader world hemophilia population. Most research has been directed at overcoming the inherent limitations of rFVIII expression and the inhibitor response. This includes techniques to improve rFVIII biosynthesis and secretion, functional activity, half-life and antigenicity/immunogenicity. Some of these proteins have already reached commercialization and have been utilized in gene therapy strategies, while others are being evaluated in pre-clinical studies. These novel proteins partnered with advances in gene transfer vector design and delivery may ultimately achieve persistent expression of FVIII leading to an effective long-term treatment strategy for hemophilia A. In addition, these novel FVIII proteins could be partnered with new advances in alternative recombinant protein production in transgenic animals yielding an affordable, more abundant supply of rFVIII. Novel rFIX proteins are being considered for gene therapy strategies whereas novel rVIIa proteins are being evaluated to improve the potency and extend their plasma half-life. This review will summarize the status of current recombinant clotting factors and the development and challenges of recombinant clotting factors bioengineered for improved function.
Collapse
Affiliation(s)
- S W Pipe
- Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI 48109, USA.
| |
Collapse
|
22
|
Van Cott KE, Monahan PE, Nichols TC, Velander WH. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide. Haemophilia 2005; 10 Suppl 4:70-6. [PMID: 15479375 PMCID: PMC3925420 DOI: 10.1111/j.1365-2516.2004.00983.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Haemophilia replacement factors, both plasma-derived and recombinant, are in relatively short supply and are high-cost products. This has stymied the study and development of alternative methods of administration of haemophilia therapy even in the most economically advanced countries, owing to the large amounts of material needed because bioabsorption and bioavailability of haemophilic factors can be less than 10% when using non-intravenous routes of delivery. There is therefore a need to increase access to therapy worldwide by decreasing the cost and increasing the abundance so that therapy can be achieved through simplified, alternative delivery methods. Transgenic livestock have been used to produce haemophilic factors in milk. Only the pig mammary gland has been shown to carry out the post-translational processing necessary to enable both the biological activity and long circulation half-life needed for therapeutic glycoproteins. Furthermore, the large amounts of recombinant protein that can be produced from pig milk make feasible the use of alternative delivery methods such as oral, intratracheal, subcutaneous, and intramuscular administration.
Collapse
|
23
|
Staby A, Sand MB, Hansen RG, Jacobsen JH, Andersen LA, Gerstenberg M, Bruus UK, Jensen IH. Comparison of chromatographic ion-exchange resins. J Chromatogr A 2005; 1069:65-77. [PMID: 15844484 DOI: 10.1016/j.chroma.2004.11.094] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A comparative study was performed on heparin resins and strong and weak cation exchangers to investigate the pH dependence, efficiency, binding strength, particle size distribution, static and dynamic capacity, and scanning electron microscopy pictures of chromatographic resins. The resins tested include: Heparin Sepharose FF, SP Sepharose FF, CM Sepharose FF, Heparin Toyopearl 650 m, SP Toyopearl 650 m, CM Toyopearl 650 m, Ceramic Heparin HyperD M, Ceramic S HyperD 20, and Ceramic CM HyperD F. Testing was performed with four different proteins: anti-FVII Mab (IgG), aprotinin, lysozyme, and myoglobin. Dependence of pH on retention was generally very low for proteins with high isoelectric point (pI), though some decrease of retention with increasing pH was observed for CM Ceramic HyperD F and S Ceramic HyperD 20. Binding of anti-FVII Mab with pI < 7.5 was observed on several resins at pH 7.5. Efficiency results show the expected trend of increasing dependence of the plate height with increasing flow rate of Ceramic HyperD resins followed by Toyopearl 650 m resins and the highest flow dependence of the Sepharose FF resins corresponding to their pressure resistance. Determination of particle size distribution by two independent methods, coulter counting and SEM, was in good agreement. Binding strength of cation-exchange resins as a function of ionic strength varies depending on the protein. Binding and elution at high salt concentration may be performed with Ceramic HyperD resins, while binding and elution at low salt concentration may be performed with model proteins on heparin resins. Employing proteins with specific affinity for heparin, a much stronger binding is observed, however, some cation exchangers may still be good substitutions for heparin resins. Dynamic capacity at 10% breakthrough compared to static capacity measurements and dynamic capacity displays that approximately 40-80% of the total available capacity is utilized during chromatographic operation depending on flow rate. A general good agreement was obtained between results of this study and data obtained by others. Results of this study may be used in the selection of resins for testing during protein purification process development.
Collapse
Affiliation(s)
- Arne Staby
- Novo Nordisk A/S, Health Care Discovery and Development, Protein Separation, Hagedornsvej 1, DK-2820 Gentofte, Denmark.
| | | | | | | | | | | | | | | |
Collapse
|